![]() |
|
|
Vol. 281, Issue 1, 142-148, 1997
Department of Pharmacology, New York Medical College, Valhalla, New
York
Studies of estradiol and tamoxifen actions to modulate the actions of
thyroid hormone (triiodothyronine, T3) in the rat have shown that a
subset of estrogen responses require T3 for expression. Also, tamoxifen
acts as a partial agonist in estrogen responses that are T3
independent, but acts as a full estrogen agonist in T3-dependent
responses. This study examined whether the differing behavior of
tamoxifen (a triphenylethylene antiestrogen) in T3-independent and
T3-dependent estrogen responses would be shared with ICI 182,780, a
steroidal antiestrogen. An ovariectomized-thyroidectomized rat model
was used. Drug vehicle, tamoxifen alone (0.4 mg/kg), ICI 182,780 alone
(2 mg/kg) or tamoxifen plus ICI 182,780 were given for 3 weeks to
ovariectomized-thyroidectomized rats with or without T3 replacement (10 µg/kg). T3-independent estrogen responses measured were the induction
of uterine growth and induction of pituitary growth hormone (GH) in the
absence of T3. T3-dependent estrogen responses measured were antagonism
of T3-evoked increases in pituitary GH, body weight, tibia length and
hepatic malic enzyme, and increases in serum triglycerides. Tamoxifen
acted as a partial agonist in T3-independent estrogen responses,
whereas ICI 182,780 acted as a potent pure antagonist in such
responses; it lacked agonist efficacy and totally blocked tamoxifen
effects. In T3-dependent estrogen responses, tamoxifen acted as a full
estrogen agonist. ICI 182,780 acted as a weak agonist in some
T3-dependent responses and lacked agonist efficacy in others. Moreover,
ICI 182,780 had poor efficacy in blocking tamoxifen actions in
T3-dependent responses. The results indicate that ICI 182,780, like
tamoxifen, displays a duality in its pharmacological behavior which
pivots on the T3 dependence of the estrogen response.
This article has been cited by other articles:
![]() |
L. M. Ickenstein and S. M. Bandiera Persistent Suppression of Hepatic CYP2A1 Expression and Serum Triiodothyronine Levels by Tamoxifen in Intact Female Rats: Dose-Response Analysis and Comparison with 4-Hydroxytamoxifen, Fulvestrant (ICI 182,780), and 17beta -Estradiol-3-benzoate J. Pharmacol. Exp. Ther., August 1, 2002; 302(2): 584 - 593. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Fitts, R. M. Klein, and C. A. Powers Estrogen and Tamoxifen Interplay with T3 in Male Rats: Pharmacologically Distinct Classes of Estrogen Responses Affecting Growth, Bone, and Lipid Metabolism, and Their Relation to Serum GH and IGF-I Endocrinology, October 1, 2001; 142(10): 4223 - 4235. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Fitts, R. M. Klein, and C. A. Powers Comparison of Tamoxifen Effects on the Actions of Triiodothyronine or Growth Hormone in the Ovariectomized-Hypothyroid Rat J. Pharmacol. Exp. Ther., July 1, 1998; 286(1): 392 - 402. [Abstract] [Full Text] |
||||